explore -WSS

explore

author：Wikipedia 2025-10-01 11:45:49 - browse：745

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Change Healthcare cyberattack outage could last weeks

WSS

ALS groups 'won't be played again' by the FDA, drug sponsors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

AstraZeneca loses challenge to Medicare drug price negotiation

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Military medical care influenced by rank and race, new study finds

knowledge

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

Arc Institute generative AI designs new CRISPR systems

Continuity nursing helped my family in our darkest PICU moments

Pfizer highlights cancer drugs it thinks could reignite investor interest

Dobbs anniversary: the lost opportunity of abortion as health care

Big Tobacco's 'harm reduction': Is it for real, or a sham?

In age of alternative facts, a scholarly course on calling out crap

Military medical care influenced by rank and race, new study finds

Tori Bowie and the unacceptable rates of Black maternal death

Arc Institute generative AI designs new CRISPR systems

focus

Second House panel advances two

Kenai launches with $82 million for Parkinson’s stem cell therapy

RSV vaccines may be linked to small increased risk of developing GBS

ALS groups 'won't be played again' by the FDA, drug sponsors

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Arc Institute generative AI designs new CRISPR systems

focus

hotspot

Wikipedia

explore